4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / A Study to Evaluate the Performance and Potential Benefits of an Assistive Artificial Intelligence Device ScanNav Anatomy Peripheral Nerve Block - US V1.0 for Ultrasound-guided Regional Anesthesia

A Study to Evaluate the Performance and Potential Benefits of an Assistive Artificial Intelligence Device ScanNav Anatomy Peripheral Nerve Block - US V1.0 for Ultrasound-guided Regional Anesthesia

Study Description
Brief Summary:

This is a single-center, prospective study to be undertaken at University of Oregon, Portland, USA. The aim is to provide data on the clinical performance of ScanNav Anatomy PNB for identification of anatomical structures during UGRA scanning, in particular:

  1. Assess the benefits of the device to intended users when supervising a trainee who is performing UGRA scanning.
  2. Assess the benefits of the device when intended users perform UGRA scanning.
  3. Assess risk mitigation by the intended users when performing UGRA scanning.

Condition or disease Intervention/treatment
Ultrasound Imaging of Anatomical Structures Device: Ultrasound scanning

Show Show detailed description
Study Design
Layout table for study information
Study Type : Observational
Estimated Enrollment : 34 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Study to Evaluate the Performance and Potential Benefits of an Assistive Artificial Intelligence Device ScanNav Anatomy Peripheral Nerve Block - US V1.0 for Ultrasound-guided Regional Anesthesia
Actual Study Start Date : May 16, 2021
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : November 2021
Arms and Interventions
Group/Cohort Intervention/treatment
Participant
All 15 participants must be anesthesiologists who are competent to perform UGRA independently. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified and licensed Medical Doctor.
Device: Ultrasound scanning
All participants will scan with and without device and trainee on 4 models. The order of the device assistance and models will be randomized between participants, but participant will always have exposure to device first before supervising the trainee.

Trainee
All 15 trainees must be healthcare practitioners who are licensed to perform UGRA. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified health practitioner
Device: Ultrasound scanning
All participants will scan with and without device and trainee on 4 models. The order of the device assistance and models will be randomized between participants, but participant will always have exposure to device first before supervising the trainee.

Outcome Measures
Primary Outcome Measures :
  1. Obtaining the correct ultrasound view [ Time Frame: 6 months ]
    Number of participants obtaining the correct ultrasound view [majority view, at least 8/15 participants in agreement]


Secondary Outcome Measures :
  1. Identifying anatomical structures [ Time Frame: 6 months ]
    Number of participants identifying the correct anatomical structures in adult patients up to BMI 35 kg/m2 [majority view, at least 8/15 participants in agreement]

  2. Effect of supervision in anatomical structure identification [ Time Frame: 6 months ]
    Number of participants identifying the correct anatomical structures while being supervised in UGRA scanning [majority view, at least 8/15 participants in agreement]

  3. Measuring operator confidence [ Time Frame: 6 months ]
    Number of participants with improved confidence [majority view, at least 8/15 participants in agreement]

  4. Number of errors in anatomy recognition by participants [ Time Frame: 6 months ]
    Number of errors in anatomy recognition by participants [per class of safety critical structure, for all models]


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Participants All participants must be anesthesiologists who are competent to perform UGRA independently. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified and licensed Medical Doctor.

Trainees All trainees must be healthcare practitioners who are licensed to perform UGRA. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified health practitioner.

Models 4 models will be selected carefully based on their BMI inclusion criteria.

Criteria

Participant Inclusion criteria

  1. Completed advanced training (e.g., fellowship) in or hold a qualification related to UGRA
  2. Regularly delivers direct clinical care using UGRA, including for 'awake' surgery where indicated
  3. Member of a relevant professional society (e.g., ASA, ASRA, ESRA, RA-UK)
  4. Regularly teach UGRA in the course of their clinical work, including advanced techniques where indicated

Participant exclusion criteria

  1. Unwilling or unable to provide informed consent.
  2. Involved in development of the ScanNav Anatomy PNB device.

Trainee Inclusion criteria

  1. U.S. board-eligible/board-certified health practitioner who holds a qualification licensing to perform UGRA
  2. NOT capable or confident of independent UGRA practice

Trainee exclusion criteria

  1. Unwilling or unable to provide informed consent.
  2. Involved in development of the ScanNav Anatomy PNB device.

Models Inclusion Criteria

  1. Male or female, at least 18 years of age;
  2. Able to comprehend and sign the Informed Consent prior to enrolment in the study.
  3. To fit either BMI category: BMI <30 OR BMI >=30

Model Exclusion Criteria

  1. Aged <18 years of age or over 60 years or age
  2. Unwilling or unable to provide informed consent.
  3. BMI> 39 kg/m2
  4. Known pathology of the area to be scanned.
Contacts and Locations

Locations
Layout table for location information
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97239
Sponsors and Collaborators
IntelligentUltrasound Limited
Investigators
Layout table for investigator information
Principal Investigator: Glenn Woodworth, MD Oregon Health and Science University
Principal Investigator: James Bowness, MD University of Oxford & Royal Gwent Hospital
Tracking Information
First Submitted Date May 25, 2021
First Posted Date June 9, 2021
Last Update Posted Date June 9, 2021
Actual Study Start Date May 16, 2021
Estimated Primary Completion Date August 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: June 1, 2021)
Obtaining the correct ultrasound view [ Time Frame: 6 months ]
Number of participants obtaining the correct ultrasound view [majority view, at least 8/15 participants in agreement]
Original Primary Outcome Measures Same as current
Change History No Changes Posted
Current Secondary Outcome Measures
 (submitted: June 1, 2021)
  • Identifying anatomical structures [ Time Frame: 6 months ]
    Number of participants identifying the correct anatomical structures in adult patients up to BMI 35 kg/m2 [majority view, at least 8/15 participants in agreement]
  • Effect of supervision in anatomical structure identification [ Time Frame: 6 months ]
    Number of participants identifying the correct anatomical structures while being supervised in UGRA scanning [majority view, at least 8/15 participants in agreement]
  • Measuring operator confidence [ Time Frame: 6 months ]
    Number of participants with improved confidence [majority view, at least 8/15 participants in agreement]
  • Number of errors in anatomy recognition by participants [ Time Frame: 6 months ]
    Number of errors in anatomy recognition by participants [per class of safety critical structure, for all models]
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title A Study to Evaluate the Performance and Potential Benefits of an Assistive Artificial Intelligence Device ScanNav Anatomy Peripheral Nerve Block - US V1.0 for Ultrasound-guided Regional Anesthesia
Official Title A Study to Evaluate the Performance and Potential Benefits of an Assistive Artificial Intelligence Device ScanNav Anatomy Peripheral Nerve Block - US V1.0 for Ultrasound-guided Regional Anesthesia
Brief Summary

This is a single-center, prospective study to be undertaken at University of Oregon, Portland, USA. The aim is to provide data on the clinical performance of ScanNav Anatomy PNB for identification of anatomical structures during UGRA scanning, in particular:

  1. Assess the benefits of the device to intended users when supervising a trainee who is performing UGRA scanning.
  2. Assess the benefits of the device when intended users perform UGRA scanning.
  3. Assess risk mitigation by the intended users when performing UGRA scanning.
Detailed Description

Background:

The American Society of Regional Anesthesia and Pain Medicine (ASRA) has published evidence-based assessment of ultrasound-guided regional anesthesia (Neal et al., 2010) concluding that ultrasound guidance is superior or equal to other non-ultrasound nerve localization techniques. A subsequent publication from ASRA (Neal et al., 2016), has strengthened their position of ultrasound guidance being superior than other methods, including for the reduction of local anesthetic systemic toxicity. However, ultrasound-guided regional anesthesia (UGRA) is a difficult technique to master. A key activity of UGRA is ultrasound image interpretation (Sites et al., 2009) which ScanNav Anatomy PNB is designed to support.

Methodology:

15 participants (anesthesiologists capable of independently performing UGRA) will be recruited to evaluate the performance and benefit of ScanNav Anatomy PNB device in person, by scanning 2 healthy models (n=1 BMI<30, n=1 BMI>=30 kg/m2).

The device performance and benefits will be ascertained once the scanning session for each block is complete by use of a structured questionnaire.

  • Participants will be asked to scan a model with and without the use of ScanNav Anatomy PNB. The order of with/without the device will be randomized between participants.
  • Participants will also be asked to supervise a trainee (another healthcare professional qualified to perform the UGRA procedure under supervision) while they are scanning models with and without ScanNav Anatomy PNB aid. The participant will always use the device first before supervising the trainee.
  • The above will be performed on 2 models from different BMI categories (n=1 BMI<30, n=1 BMI>=30 kg/m2; total scans n=16).
  • The order of models will be randomized between participants.
  • All 9 supported regions will be evaluated; each region will be scanned/evaluated at least 3 times.

Data collection

- Participants and trainees will be asked to complete a structured questionnaire to assess the device performance and clinical benefits at the end of scanning for the block.

Data analysis:

  • Data will be aggregated and evaluated on safety critical structure type basis.
  • Quantitative data obtained from the participants will be presented as frequencies and expressed as percent of total or as mean ± s.d. where appropriate.

The collected data and overall performance and benefits of ScanNav Anatomy PNB will be evaluated and summarized by presence and absence of ScanNav Anatomy PNB assistance, trainee and stratified by low/high BMI model.

Independent expert evaluation

  • The scans be recorded during the study sessions. These scans will be post processed to short clips (10 seconds prior to obtaining optimum view) and sent for evaluation to an independent expert panel.
  • The expert panel will be asked to evaluate the scans and the ScanNav Anatomy PNB highlighting performance independently from the participant. The majority opinion (at least 2/3) will be obtained to establish the agreement (e.g., yes/yes/no = yes)
  • The answers obtained during the scan session from participants will be compared to expert panel view. Independent comparisons between performance assessment will be made, providing that the expert panel view is the 'ground truth'.
  • Data will be evaluated and presented by safety structure on each model and overall (i.e., total for each class of safety critical structure; nerve, artery etc.).
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population

Participants All participants must be anesthesiologists who are competent to perform UGRA independently. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified and licensed Medical Doctor.

Trainees All trainees must be healthcare practitioners who are licensed to perform UGRA. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified health practitioner.

Models 4 models will be selected carefully based on their BMI inclusion criteria.

Condition Ultrasound Imaging of Anatomical Structures
Intervention Device: Ultrasound scanning
All participants will scan with and without device and trainee on 4 models. The order of the device assistance and models will be randomized between participants, but participant will always have exposure to device first before supervising the trainee.
Study Groups/Cohorts
  • Participant
    All 15 participants must be anesthesiologists who are competent to perform UGRA independently. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified and licensed Medical Doctor.
    Intervention: Device: Ultrasound scanning
  • Trainee
    All 15 trainees must be healthcare practitioners who are licensed to perform UGRA. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified health practitioner
    Intervention: Device: Ultrasound scanning
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Enrolling by invitation
Estimated Enrollment
 (submitted: June 1, 2021)
34
Original Estimated Enrollment Same as current
Estimated Study Completion Date November 2021
Estimated Primary Completion Date August 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria

Participant Inclusion criteria

  1. Completed advanced training (e.g., fellowship) in or hold a qualification related to UGRA
  2. Regularly delivers direct clinical care using UGRA, including for 'awake' surgery where indicated
  3. Member of a relevant professional society (e.g., ASA, ASRA, ESRA, RA-UK)
  4. Regularly teach UGRA in the course of their clinical work, including advanced techniques where indicated

Participant exclusion criteria

  1. Unwilling or unable to provide informed consent.
  2. Involved in development of the ScanNav Anatomy PNB device.

Trainee Inclusion criteria

  1. U.S. board-eligible/board-certified health practitioner who holds a qualification licensing to perform UGRA
  2. NOT capable or confident of independent UGRA practice

Trainee exclusion criteria

  1. Unwilling or unable to provide informed consent.
  2. Involved in development of the ScanNav Anatomy PNB device.

Models Inclusion Criteria

  1. Male or female, at least 18 years of age;
  2. Able to comprehend and sign the Informed Consent prior to enrolment in the study.
  3. To fit either BMI category: BMI <30 OR BMI >=30

Model Exclusion Criteria

  1. Aged <18 years of age or over 60 years or age
  2. Unwilling or unable to provide informed consent.
  3. BMI> 39 kg/m2
  4. Known pathology of the area to be scanned.
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT04918693
Other Study ID Numbers IU2021_AG_08
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party IntelligentUltrasound Limited
Study Sponsor IntelligentUltrasound Limited
Collaborators Not Provided
Investigators
Principal Investigator: Glenn Woodworth, MD Oregon Health and Science University
Principal Investigator: James Bowness, MD University of Oxford & Royal Gwent Hospital
PRS Account IntelligentUltrasound Limited
Verification Date June 2021